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Abstract
Objectives We study a cohort of Medicare-insured men
and women aged 65? in the year 2000, who lived in 11
states covered by Surveillance, Epidemiology, and End
Results (SEER) cancer registries, to better understand
various predictors of endoscopic colorectal cancer (CRC)
screening.
Methods We use multilevel probit regression on two
cross-sectional periods (2000–2002, 2003–2005) and
include people diagnosed with breast cancer, CRC, or
inﬂammatory bowel disease (IBD) and a reference sample
without cancer.
Results Men are not universally more likely to be
screened than women, and African Americans, Native
Americans, and Hispanics are not universally less likely to
be screened than whites. Disparities decrease over time,
suggesting that whites were ﬁrst to take advantage of an
expansion in Medicare beneﬁts to cover endoscopic
screening for CRC. Higher-risk persons had much higher
utilization, while older persons and beneﬁciaries receiving
ﬁnancial assistance for Part B coverage had lower utiliza-
tion and the gap widened over time.
Conclusions Screening for CRC in our Medicare-insured
sample was less than optimal, and reasons varied consid-
erably across states. Negative managed care spillovers
were observed, demonstrating that policy interventions to
improve screening rates should reﬂect local market con-
ditions as well as population diversity.
Keywords Colorectal cancer screening  Spatial
heterogeneity  Utilization disparities  Socio-ecological
model  Spatial interaction  Managed care spillover
Introduction
Although colorectal cancer (CRC) is one of the few neo-
plastic diseases that can be prevented through screening,
and survival rates are 90% if diagnosed early, only 39% of
CRC cases are diagnosed at an early stage. Age-speciﬁc
incidence and mortality rates show that most cases are
diagnosed after age 50, so screening recommendations
target people aged 50 or older [1–3]. In 2004, only 45.1%
of the over-50 population had received endoscopic CRC
screening within the 5-year interval 2000–2004 [4]. This
increased to 55.7% within the 10-year interval 1997–2006
[5]. These national statistics suggest that CRC screening
rates are increasing slowly over time for both men and
women but remain suboptimal and are higher for men than
for women [5–9]. CRC remains the second leading cause of
cancer deaths in the United States [10, 11], so meeting
screening guidelines is important.
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risk groups account for only about a one quarter of the
CRC incidence. Thus, regular population screening is
important because any policy limiting screening to high-
risk groups would miss the majority of CRC cases [3].
However, it is especially important for high-risk groups to
be screened regularly, which may include people with
previous breast cancer or CRC and inﬂammatory bowel
disease (IBD).
The literature offers conﬂicting evidence regarding
whether breast cancer survivors have greater risk for CRC
[12–16], but the National Cancer Institute includes a per-
sonal history of breast cancer as a CRC risk factor [17].
IBD is associated with increased risk of CRC [18], and
continuous endoscopic surveillance is recommended for
persons with IBD [19]. Continuous endoscopic surveillance
is also recommended for CRC patients and survivors [20].
The recommended short 1-year interval for surveillance
colonoscopy following CRC resection has been shown to
be a clinically efﬁcient and cost-effective strategy for
improving detection and reducing mortality [21].
The main objective of this paper is to study a large
elderly population that is well insured by fee-for-service
(FFS) Medicare, including persons with known risk factors
for CRC, to determine the personal and environmental
factors that are important predictors of CRC screening
utilization and to examine trends in utilization over time.
Since 1998, Medicare has covered sigmoidoscopy every
4 years for all persons over age 50 and colonoscopy every
2 years for persons at high risk for CRC. With beneﬁts
expansion in 2001, Medicare now covers colonoscopy
every 10 years for persons of average risk [22, 23].
During our study period, a controversy arose in the
medical literature regarding appropriate endoscopy use for
CRC screening in elders, considering their increased risk of
adverse outcomes from endoscopic tests [24–26]. In 2008,
the U.S. Preventive Services Task Force (USPSTF) rec-
ommended that CRC screening should decline with age
and recommended against endoscopic screening for per-
sons aged 85? [25].
Along with personal factors, such as age, we examine
environmental factors reﬂecting service supply and the
spatial interaction of people and their environments along
the pathways to endoscopic CRC screening. We study two
time periods (2000–2002 and 2003–2005) to assess chan-
ges in relationships over time. We use multilevel probit
regression of the binary outcome ‘‘whether screening was
utilized,’’ examining people in 11 states in separate
regressions. Recent descriptive work has demonstrated
considerable geographic variation in endoscopic CRC test
use across states [22], which we explore fully in state-
speciﬁc regressions. We advance the literature by exam-
ining multiple, multilevel factors associated with the varied
geospatial outcomes. We focus on the following research
questions and examine differences across the states and
over time:
1. After adjusting for other factors, are there disparities in
endoscopy use by sex, race, or ethnicity?
2. After adjusting for other factors, is there lower
endoscopy use by needy elderly who receive assistance
for paying Part B premiums (covering endoscopy
services)?
3. After adjusting for other factors, how pronounced is
the decline in use with age?
4. After adjusting for other factors, is endoscopy utiliza-
tion higher among high-risk populations?
5. Are there signiﬁcant Medicare managed care market
penetration spillover effects on the propensity to utilize
endoscopic CRC screening by the FFS Medicare
population?
We perform parallel empirical analyses in an early
(2000–2002) and later (2003–2005) time period using a
cohort of people present in both periods to assess dispari-
ties over time in response to the Medicare beneﬁt expan-
sion that began in the early period and the emerging
guidelines, which recommend decreased endoscopic
screening with advancing age.
Methods
Study population
Our study population is a cohort of 272,077 men and
women in 11 states aged 65 or older in the year 2000,
enrolled in FFS Medicare (both Part A and Part B) in 2000,
and remaining alive over the period 2000–2005. Beneﬁ-
ciaries who subsequently lost or dropped Medicare Part B
(elective coverage that can be purchased to cover outpa-
tient services, such as endoscopy) or who had Medicare
managed care coverage during the period would have
incomplete claims histories for endoscopic procedures.
Less than 1.5% of the study population was without com-
plete FFS coverage for the entire period, and we kept them
in the sample and controlled statistically for their ‘‘variable
insurance’’ coverage over the period (variables: months
without Part B, months with Medicare managed care
coverage). Thus, our cohort represents the typical insur-
ance experience of Medicare beneﬁciaries who were
encouraged to try Medicare managed care organizations
during this period. Beneﬁciaries could voluntarily enroll
and disenroll from Medicare managed care organizations
on a monthly basis, and plan switching and returning to
FFS Medicare was common as Medicare beneﬁciaries
shopped around for the best value [27, 28]. Thus, even
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123though our sample members were primarily in FFS
Medicare, they had neighbors with Medicare managed care
coverage, and some tried it themselves. Because the SEER-
Medicare database has higher representation in markets
where Medicare managed care is well established, we use
this situation to examine the results for indication of
Medicare managed care spillover effects onto our Medicare
FFS population.
Conceptual model and sample statistics
Our conceptual model (Fig. 1) is a hybrid of several
models from the behavioral health, socio-ecological, and
health geography ﬁelds [29–31]. This conceptual model
situates the individual decision maker—characterized by
enabling, predisposing, and need constructs from the
classic Aday model [32]—into an ecological context that
has different zones of inﬂuence deﬁned as Fundamental/
Macro, Intermediate/Community, Interpersonal/Proximate,
and Individual/Population. Many factors at the different
levels of hierarchy are included in the conceptual model
diagram. We are not able to include variables reﬂecting all
of these constructs in our empirical work, because data are
not available. However, in future research, inclusion of
these omitted variables may provide new insights. Con-
structs represented by variables included in our model are
highlighted in bold text in Fig. 1.
All variables used in the regression modeling and their
sources are described in Appendix Table 3, which is divi-
ded into three sections corresponding to the conceptual
model. Person-level sample statistics are presented in
Appendix Table 4. Intermediate, community-level factors
are deﬁned at the county level, reﬂecting the political units
deﬁned to manage the public ﬁnances associated with
community services. The Interpersonal, neighborhood-
level factors are deﬁned at a smaller geographic resolution
than the community factors, the primary care service area
(PCSA). PCSAs are natural primary care physician markets
derived by Dartmouth researchers using Medicare patient
ﬂows to primary care physicians, which have been vali-
dated in previous work [29, 30, 33, 34]. PCSA and county-
level variable sample statistics are presented in Appendix
Tables 5 and 6.
We include a new measure of Medicare managed care
penetration at the PCSA level in the regression equation,
which we derived from 100% Medicare denominator ﬁles.
In previous studies, Medicare managed care penetration
has always been measured at the county level, because
county-level data are publicly available. PCSAs are argu-
ably more appropriate as market areas for managed care
than counties, because they reﬂect primary care markets.
As shown by comparing Appendix Tables 5 and 6, PCSAs
are much more numerous and smaller than counties; the
state of Connecticut, for example, has eight counties cov-
ered by 71 PCSAs.
Statistical analysis
Our outcome of interest is endoscopic procedure utiliza-
tion, deﬁned as any type or amount of endoscopic
Fundamental/Macro Factors: Distribution of Wealth, Educational Opportunities, and Political Influence; Social and 
Economic Policies; Institutions; Regulations; Campaigns; Topography, Climate, Water Supply
Personal Health Behavior: Utilization of 
CRC Screening 
Intermediate or Community  
Social Context: Neighborhood, 
Workplace, and Housing Conditions; 
Public Infrastructure and Investment; 
Police, Enforcement Services, Crime; 
Area Poverty; Area Educational 
Attainment  
Physical Environment: Community 
Capacity and Partnership; Land Use 
Patterns, Transportation Conditions, 
Buildings, Public Resources, Pollution, 
Population Density 
Interpersonal  
Stressors; Social Integration and 
Support; Psychosocial Factors; 
Behavioral Settings; Social 
Relationships; Living Conditions; 
Neighborhoods and Communities; 
Neighborhood Watchfulness; 
Driver Courtesy; Social or 
Cultural Cohesion ; Population 
Health Behaviors or Norms
Individual/Population  
Enabling/Disabling
• Personal Disability 
• Personal Resources 
• Type of Health Coverage 
• New Address 
• Marital Status 
• Employment Status 
Predisposing
• Age, Sex, Gender 
• Race or Ethnicity 
• Educational Attainment 
Need
• Beliefs, Family History 
• Perceived Risk 
• Health Status 
Health Care System 
Proximity and Density of Facilities, 
Physicians, Specialists 
Crowding, Scheduling Convenience 
Personal Physician 
Managed Care Climate 
Fig. 1 Socio-ecological multilevel model of colorectal cancer screening behavior
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123procedure use over each 3-year period. We estimate mul-
tilevel probit models of the probability of using endoscopic
procedures and include person-level, PCSA, and county-
level covariates, following our conceptual model (see
Fig. 1). We use generalized estimating equations (GEE) to
adjust the standard errors of area-level variables to reduce
the efﬁciency bias caused by redundancy (repeated mea-
sures over all people in the area) [35–37].
Pooling states together in a single empirical model with
ﬁxed effects to produce some ‘‘national’’ results may not
make statistical sense when there is interest in the con-
siderable heterogeneity that exists across the states [31].
We estimate each state model as a separate regression, with
two time periods: early (2000–2002) and late (2003–2005).
Results
As presented in Table 1, across the 11 states we study,
between 45 and 53% of the study cohort used endoscopy
services at least once over the 6-year period 2000–2005,
which is far from optimal. This population is well insured
by Medicare, which expanded beneﬁts to cover this service
for people of average risk in 2001, so the low use rates are
a concern. Table 1 presents that the proportion of people
who used endoscopy at least twice over 2000–2005 ranges
from 14 to 19% across the 11 states. These repeat users are
probably persons at higher risk for CRC than the average
person in the cohort (those with breast cancer or CRC
diagnosis or IBD).
To save space and sharpen the focus, we do not discuss
all of the empirical results from our estimation, although
these are provided for interested readers in Table 2.
Table 2 presents state-speciﬁc results with early and late
time periods in adjacent columns for each state. Only the
coefﬁcient estimates that were statistically signiﬁcant at
the 5% level or better are included in the table with the
exception of the last variable, where p values (in paren-
thesis) follow the estimates (managed care spillover
effects). We include weaker results, signiﬁcant at the 10%
level or better, for the managed care spillover effects
variable because of the policy importance of this effect,
which reﬂects the degree of Medicare managed care
spillover effects on FFS Medicare beneﬁciaries. The last
row of the table is the model prediction success rate,
which is good, ranging from 71 to 80% across the states
and time.
In Figs. 2, 3, 4, 5, and 6, we present the results that can
help answer the ﬁve main study questions. The results
portrayed are effect estimates from the binary probit
model, interpreted as marginal probability effects that arise
from the fully speciﬁed/fully adjusted empirical model (see
Table 2).
Disparities by gender, race, or ethnicity
Women appear less likely to use endoscopy than men in all
but four states: Georgia, New Mexico, Kentucky, and
Louisiana. In Georgia and New Mexico, there is no dif-
ference; in Kentucky and Louisiana, women are more
likely to use these services than men. Figure 2 illustrates
the relative difference in the propensity for women versus
men to use endoscopic screening for CRC over time, as the
cohorts age. A negative 0.03 is interpreted as ‘‘females are
Table 1 Use of endoscopy in 2000–2005 by sample cohort of well-insured persons (cohort aged 65? in the year 2000, followed through 2005)
State Sample size
in state
Proportion with any
use in 2000–2002
Proportion with any use in
2003–2005 but not 2000–2002
Proportion with any
use in both periods
Proportion with any
use in 2000–2005
CA 86,843 0.31 0.23 0.14 0.47
CT 23,402 0.36 0.27 0.17 0.53
GA 10,316 0.37 0.26 0.17 0.53
IA 22,799 0.38 0.24 0.19 0.53
KY 18,203 0.32 0.23 0.15 0.47
LA 15,717 0.29 0.23 0.14 0.46
MI 25,692 0.37 0.25 0.19 0.53
NJ 35,378 0.33 0.23 0.17 0.48
NM 7,439 0.30 0.21 0.14 0.45
UT 8,777 0.34 0.26 0.15 0.51
WA 17,511 0.34 0.26 0.15 0.51
We used the following codes on Medicare claims to identify endoscopy use:
CPT codes: 44388–44397, 45300–45392; HCPCS codes: G0104, G0105, G0121; and ICD-9-CM codes: 45.22–45.25, 45.41–45.43, 48.22–48.24,
48.36
We used ICD-9-CM codes 555.x and 556.x listed on the Medicare claims to identify persons with IBD
448 Cancer Causes Control (2010) 21:445–461
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1233% less likely, on average, than males to use endoscopy in
this state and time period.’’
Race and ethnicity effects vary across the states. Blacks
are signiﬁcantly less likely to use endoscopy than whites in
several states: California, Georgia, Kentucky, Louisiana,
and New Jersey (see Fig. 3). However, disparities appear to
have narrowed over time. By the later period, black–white
disparities existed for only two states—Georgia and Lou-
isiana—and they were smaller than in the previous period.
In two states (Michigan and Utah), disparities were in the
opposite direction: blacks were signiﬁcantly more likely
than whites to use endoscopy. In California and New
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Fig. 2 Relative propensity to
use endoscopic services among
a female cohort when compared
with a male cohort by state and
time, in early (2000–2002) and
late (2003–2005) periods
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Fig. 3 Relative propensity to
use endoscopic services among
minority groups relative to
whites by state and time, in
early (2000–2002) and late
(2003–2005) periods
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Fig. 4 Proportion of aged
beneﬁciaries in the states who
are dually eligible, and the
estimated effect of dual
eligibility on use, in early
(2000–2002) and late (2003–
2005) periods
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123Mexico, Hispanics and Native Americans had lower
probability of use (4–6%) than whites. Hispanics had much
lower probability of use than whites in Utah (about 15%
lower) but higher probability of use than whites in New
Jersey (about 6% higher). Asians had lower probability of
use than whites in Michigan and New Jersey (about 10%
lower). Native Americans had higher probability of use
than whites in Washington (about 9% higher). In two states
(Connecticut and Iowa), there were no observed statisti-
cally signiﬁcant racial or ethnic disparities in the predicted
probability of endoscopy use.
Financial need
Having dual eligibility for Medicare and Medicaid, with
extra resources to purchase Part B coverage, is associated
with lower probability of use in every state and in both time
periods. This variable is indicative of lower ﬁnancial
means, and ﬁndings demonstrate that the poorer elderly are
less inclined to use these services, even when covered by
Part B insurance. Figure 4 shows a state-level variable, the
proportion of aged beneﬁciaries in the states who are dually
eligible (black, gray), as background to help interpret the
estimated effect of dual eligibility on use (striped, spotted),
for the early (2000–2002) and late (2003–2005) time
periods. In Utah, Iowa, and Washington, these estimated
effects are large, suggesting at least 10% lower probability
of use for dually eligible seniors. California is the only
state with an increasing proportion of dually eligible
seniors statewide coupled with a decline in the estimated
reduction in propensity to use endoscopy over time, sug-
gesting increased social support for this subgroup. More
research may be needed regarding other factors that dis-
courage utilization by low-income seniors, such as social
support or cultural factors that may discourage use.
Effects of aging
National CRC incidence rates from the period 1998–2002
by age from the National Cancer Institute [1] show that
people aged 65–74 accounted for 26% of incidence,
whereas those aged 75–84 accounted for 29.2% of
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Fig. 5 Decline in probability of
endoscopy utilization with age,
relative to the youngest age
group (aged 65–72), in early
(2000–2002) and late (2003–
2005) periods
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Fig. 6 Endoscopy use by breast
cancer and colorectal cancer
survivors and those with
inﬂammatory bowel disease, in
early (2000–2002) and late
(2003–2005) periods
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123incidence and those aged 85? accounted for 12.6% of
incidence. Thus, in our cohort of people aged 65? in the
year 2000, the national incidence rates cited above sug-
gest that screening of older beneﬁciaries was quite
important.
Our data span the time when Medicare coverage was
expanded to include screening for persons of average risk.
In the early period (2000–2002), we would expect to see
higher use by older persons (aged 73?) than younger
persons (aged 65–72) if utilization was based solely on
risk. Instead, our data show that the estimated probability
of utilization declined with advancing age group. Relative
to the youngest group (aged 65–72), use was lower in the
middle group (aged 73–80) and even lower in the oldest
group (aged 80?). These age disparities are shown by
state in Fig. 5. Connecticut shows the greatest disparity in
use with age, and 7 of 11 states show at least 10% lower
use among the oldest group relative to the youngest
group.
Utilization by high-risk populations
Persons with IBD and breast cancer survivors may be at
higher risk for developing CRC, and continuous endo-
scopic surveillance is recommended for CRC patients and
survivors. Thus, we would expect to see higher utilization
rates for these groups if greater risk translates into greater
utilization of screening. Figure 6 shows the estimated
impacts of these three factors relative to persons without
these factors, in the early and late periods. Among the
states, Utah exhibits the highest endoscopy use by breast
cancer survivors and those with IBD, relative to others in
the population without these conditions. In every state,
utilization by CRC patients and survivors and persons with
IBD is much greater than for persons without these con-
ditions. It is interesting that for CRC patients and survivors,
use drops over time as the cohort ages. This is not uni-
versally true for persons with IBD, where in six states use
increases as the cohort ages.
Managed care spillover effects
Greater penetration by managed care can change the way
medicine is practiced in an area, with spillover effects on
FFS Medicare costs and outcomes [39]. However, the
evidence of managed care’s impacts on the use of pre-
ventive services is not consistent. Breast cancer screening
rates may be higher in regions with higher HMO penetra-
tion in Medicare and the private sector [40–42]. Increased
cancer screening of various types has been associated with
HMO enrollment [43]. Although use of endoscopic pro-
cedures for CRC screening was not examined, HMOs
promoted the use of fecal occult blood testing (FOBT) for
CRC [43]. Few studies have examined the impact of
managed care on endoscopic CRC screening. However, a
recent study using the Medicare Current Beneﬁciary Sur-
vey found that Medicare managed care plans seemed to
favor FOBT over endoscopic procedures, when compared
to FFS Medicare [44]. FOBT can detect cancer, but
endoscopic procedures, which cost more, can actually
prevent cancer by removal of precancerous lesions. One
study by Ponce et al. [45] found that the type of managed
care market structure may affect endoscopy use rates, with
associated disparities in use for minorities versus whites.
Thus, whether or not HMO presence in the market spills
over positively (or negatively) to increase (or decrease)
utilization of endoscopy by older persons with FFS
Medicare is an empirical question.
The last variable in Table 2 is the Medicare penetration
of local PCSA markets. When the estimated effect of this
variable is positive (Iowa), the spillover effect from
Medicare HMOs in the market is positive. When it is
negative, the spillover effect is negative. In our data, only
Iowa exhibits positive Medicare managed care spillover
effects; other states show negative spillover effects (Cali-
fornia, Connecticut, Louisiana, Michigan, New Jersey,
New Mexico, Utah, and Washington). Only Georgia and
Kentucky show no HMO spillover effects. These ﬁndings
warrant further study, which is policy relevant but beyond
the scope of this paper.
Discussion
Strengths and limitations
The Surveillance, Epidemiology, and End Result (SEER)-
Medicare database chosen for the study population in this
paper is ideal for several reasons. The database combines
men and women with a previous breast cancer or CRC
diagnosis from the cancer registry populations in 11 states,
combined with a randomly selected reference sample of
people without a previous cancer diagnosis from the
Medicare 5% enrollment ﬁles. All Medicare claims sub-
mitted by physicians or outpatient facilities are available
for both populations, which allow us to identify those with
IBD. The SEER-Medicare database provides a large, only
somewhat representative sample of the Medicare popula-
tion; thus, it cannot be used to generalize to national-level
statistics. However, it provides a sample that is useful for
examining utilization behavior in different states, which
are well represented.
The complete 5% Medicare sample is randomly drawn
and thus expected to be nationally representative, but the
11-state portion of it (covered by the 11 SEER cancer
registries) may not be nationally representative. Similarly,
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sentative of all persons with cancer. However, the people
aged 65 and older residing in the SEER registry states are
known to be comparable to those in the non-SEER states
based on age and sex distributions [46]. The SEER registry
states have slightly more afﬂuent, more urban populations
and a higher proportion of non-white individuals than the
non-SEER states, and the SEER cancer registry population
has lower mortality than cancer populations in non-SEER
states [46]. Thus, our study sample is slightly more urban,
wealthier, more ethnic, and less likely to die from cancer
than populations in the states we do not study. The main
advantage of using these SEER-Medicare data for the
analysisisthatbreastcancerandCRC survivorsand persons
with IBD can be identiﬁed and included in the study. Con-
tinued screening is especially important for these groups, as
notedearlier.AnotheradvantageisthattheSEERareashave
much higher penetration by Medicare HMOs than non-
SEER areas [46], making them more useful for assessing
whethertherearesigniﬁcantmanagedcarepracticespillover
effects, one of our main study questions.
Discussion of ﬁndings
Other variables in Table 2 thought to impede utilization of
endoscopy for CRC screening are related to transportation
and travel: distance to closest endoscopy provider, com-
muter intensity, or having recently moved to a new resi-
dential ZIP code. Distance to closest provider is signiﬁcant
in only four states (California, Kentucky, New Jersey, and
Washington), and effects are very small (1–3% decrease in
probability of use for a 10 mile farther facility). This effect
is small because 10 miles is a large change relative to the
norms of travel indicated by sample statistics (mean dis-
tance is between 1 and 5 miles among the states, with 10
miles representing about 2 standard deviations from the
mean). Commuter intensity has a negative effect in Cali-
fornia, Iowa, and Kentucky, as expected if greater com-
muter intensity makes driving more unpleasant for the
elderly. However, this is not the case in two states where
the estimated effect of commuter intensity is positive
(Connecticut and Washington). Having moved to a dif-
ferent ZIP code has a negative effect on probability of
endoscopy use in six states (California, Connecticut,
Georgia, Michigan, New Jersey, and Washington) and
ranges from -2% in California to -5% in Connecticut.
This effect is much larger than the effect of increasing
distance to closest provider by 10 miles. Taken together,
these ﬁndings suggest that for elective services, such as
endoscopy, distance to closest provider is less important
than local driving conditions or being disrupted by moving
or unfamiliar with the best routes to or from one’s neigh-
borhood, a byproduct of moving to a new residence.
Higher residential racial or ethnic segregation at the
local neighborhood level may either improve or impede
social integration and support [30, 31, 47–50]. Findings
demonstrate that residential segregation affects endos-
copy use differently across the states and over time, with
sometimes positive and sometimes negative effects.
Thus, we cannot conclude that living in residentially
segregated neighborhoods is necessarily detrimental to
preventive health behaviors. Other factors thought to be
associated with use are acculturation, area poverty, and
supply of providers. Acculturation factors, which reﬂect
differences in the ability to speak English by recent
versus historical immigrants from other countries, have
been found to be important for Latinos [51]. We ﬁnd
that living in communities where a greater proportion of
the elderly have poor English language ability is asso-
ciated with lower endoscopy use in California, Iowa, and
Kentucky. Living in communities with a greater pro-
portion of elderly in poverty has a negative effect in
Connecticut, Kentucky, Louisiana, New Mexico, Utah,
and Washington, and a positive effect in California and
Iowa. The positive effect in California is consistent with
the growing dually eligible population there and
observed improvements in their utilization of endoscopy
over time, noted earlier.
Several recent studies have highlighted the need to
assess the capacity available to perform endoscopy to
detect CRC [52–57]. In 2002, 14.2 million colonoscopies
were performed; this number was anticipated to increase
because of the increased use of colonoscopies for screening
and the general aging of the population. Because capacity
varies across the country, geographic differences in avail-
ability are likely to persist, if not increase. However, we
ﬁnd that the density of endoscopy providers has a positive
effect in only two of the 11 study states: Connecticut and
Iowa. We also examine density of medical specialists
associated with endoscopy supply, such as gastroenterolo-
gists and oncologists. We ﬁnd that the density of oncolo-
gists per thousand elderly is associated with lower
endoscopy use in California, Iowa, and Louisiana but
higher use in Michigan, New Jersey, and Utah, with mixed
ﬁndings for Washington. The density of gastroenterologists
greatly increases use in California (20% higher probability
per additional gastroenterologist per thousand elderly) with
more modest positive effects in New Mexico (?12%) and
Louisiana (?5–8%).
Answers to main research questions
National statistics suggest that women and minorities are
less likely to use endoscopy than men or whites. We ﬁnd
that national statistics conceal local variation that goes
against the norm, based on the 11 states we study. For
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123example, we ﬁnd that women in Kentucky and Louisiana
had slightly (1–2%) higher probability to use endoscopy
services than men in their states. Also, African Americans
in Michigan and Utah had higher probability to use
endoscopy than whites in those states (2.5 and 5.6%,
respectively), Hispanics had higher probability to use ser-
vices than whites in New Jersey (6%), and Native Ameri-
cans had higher probability to use services than whites in
Washington (8.7%). More generally, we ﬁnd that dispari-
ties in utilization among whites, African Americans, and
Hispanics narrowed over time. These ﬁndings suggest that
whites were ﬁrst to take advantage of the expansion in
Medicare coverage in most states. Perhaps, state compre-
hensive cancer control efforts help tip the balance in favor
of minorities in some states.
Results demonstrate that breast cancer survivors are
more likely to use endoscopy, as are CRC patients and
survivors and persons with IBD. These are higher-risk
groups, so higher probability of use among them is optimal
and suggests that translational medicine is being practiced.
However, observed trends in endoscopy use with age
(another risk factor) are cause for concern. Although older
people (aged 75 or older) are more likely to be diagnosed
with CRC than younger elderly (aged 65–74) [1], our data
demonstrate that the probability of endoscopy use is much
lower for older than for younger seniors. Another cause for
concern is the lower use of endoscopy for ﬁnancially needy
elderly with ﬁnancial assistance to pay Part B premiums
that cover endoscopy services. Even with this assistance,
dually eligible elderly in every state studied were signiﬁ-
cantly less likely to utilize endoscopy, ranging from about
3 to 12% lower probability of use and worsening over time
(in most states) as the cohort aged. Apparently, there are
other factors besides insurance coverage that impact utili-
zation of these preventive services by ﬁnancially needy
elderly.
In contrast to an emerging literature ﬁnding positive
spillover effects from managed care penetration on local
area practices, we ﬁnd that Medicare managed care pene-
tration in the local primary care services market has neg-
ative spillovers on endoscopy utilization by FFS Medicare
patients in several states (California, Connecticut, Louisi-
ana, New Jersey, New Mexico, Utah, and Washington).
The only state where spillovers are positive is Iowa. This
negative spillover result is consistent with ﬁndings in a
recent paper by Schneider et al. [44] that Medicare man-
aged care practice favors FOBT over endoscopy use for
persons enrolled in Medicare managed care organizations,
when compared to FFS Medicare enrollees. Thus, Medi-
care managed care practices may have spilled over in the
marketplace and discouraged the use of more expensive
endoscopic procedures. Or, perhaps higher concentration
among managed care insurers in some markets has limited
the supply of endoscopic services by discouraging entry of
providers. This negative spillover ﬁnding bears further
investigation.
Our ﬁndings support the notion that places matter—
different states show different relationships between CRC
screening and ecological and market factors. It is important
that policy interventions to improve screening rates reﬂect
local population diversity and market conditions. Optimal
policy interventions to change behavior (improve screening
rates) will be as heterogeneous as regional populations and
market conditions in the very diverse United States.
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Appendix
See Tables 3, 4, 5 and 6.
Table 3 Variables chosen for analysis, their contextual relevance, and sources
Variable Data source
Individual and population
Enabling/disabling Developed from linked California SEER cancer
registry and Medicare data, provided by the
National Cancer Institute, 2000–2003
Individual disability or ESRD as original reason for Medicare entitlement
Moved to a new ZIP code in same state, 2000–2002 or 2003–2005
Months with extra assistance from state Medicaid (dual eligibility), 2000–2002
or 2003–2005
Distance to closest endoscopy facility
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Variable Data source
Predisposing
Age in 2000
Months enrolled in a Medicare HMO anytime in 2000–2002 or 2003–2005
Enrollment in Medicare HMO during the past 2 years
Race or ethnicity (white, African American, Asian, Hispanic, Native
American, other)
Need
Had previous cancer diagnosis, breast or colorectal; had irritable bowel disease
Interpersonal factor (PCSA)
Social integration and support: isolation index describing segregation by race
or ethnicity (white, African American, Asian, Hispanic, Native American,
other), 2000
Developed from U.S. Census 2000 data at ZCTA
levels aggregated to PCSAs using HRSA’s
crosswalk: http://datawarehouse.hrsa.gov/
Stressor, driver courtesy: commuter intensity reﬂecting the proportion of the
workforce in each person’s residential area commuting 60 min or more each
way to work
Social or cultural cohesion: proportion of the elderly in each person’s
residential area with little or no English language ability, 2000
Local health norms and behaviors: Medicare managed care penetration,
deﬁned as proportion of the eligible population enrolled in Medicare
managed care plans: 2001; 2004
Built by RTI from 100% beneﬁciary denominator
ﬁles provided by the Centers for Medicare &
Medicaid Services
Intermediate/community factor (county)
Proportion of population living below the federal poverty level; GINI coefﬁcient
of household income disparity (calculated by RTI)
Census annual poverty estimates; census 2000
household income estimates
Health care system: number of endoscopy facilities per thousand elderly in each
person’s residential area, 2000–2002, 2003–2005
SEER-Medicare linked data and U.S. Census
Health care system: number of oncologists (2000, 2003), gastroenterologists
(2000, 2003), or nurses (2000, 2005) per thousand elderly (2000, 2003)
Area resource ﬁle; annual census population
estimates
SEER surveillance, epidemiology, and end results, ZCTA ZIP code tabulation area, HRSA health resources and services administration, PCSA
primary care service area
Table 4 Sample statistics for characteristics of sample population: mean followed by standard deviation
Variable CA CT GA IA KY
Sample size 86,843 23,402 10,316 22,799 18,203
Mean SD Mean SD Mean SD Mean SD Mean SD
Female 0.670 0.470 0.709 0.454 0.713 0.453 0.698 0.459 0.668 0.471
Disability or ESRD original reason for enrollment in Medicare 0.002 0.050 0.004 0.062 0.003 0.057 0.004 0.065 0.001 0.036
Age 73–80 in 2000 0.377 0.480 0.394 0.490 0.355 0.480 0.378 0.480 0.347 0.480
Age 80? in 2000 0.155 0.360 0.172 0.380 0.139 0.350 0.175 0.380 0.128 0.330
White 0.789 0.408 0.945 0.229 0.783 0.412 0.986 0.117 0.946 0.227
Asian 0.079 0.270 0.004 0.066 0.004 0.067 0.001 0.034 0.001 0.036
African American 0.045 0.207 0.039 0.193 0.204 0.403 0.008 0.092 0.050 0.217
Hispanic 0.048 0.214 0.006 0.077 0.003 0.058 0.001 0.027 0.000 0.017
Native American 0.003 0.056 0.000 0.022 0.000 0.017 0.000 0.021 0.000 0.013
All other races/ethnicities 0.036 0.185 0.006 0.077 0.005 0.071 0.003 0.056 0.003 0.052
Moved to new ZIP code 2000–2002 0.073 0.261 0.060 0.237 0.084 0.277 0.030 0.172 0.037 0.189
Moved to new ZIP code 2003–2005 0.089 0.285 0.051 0.220 0.088 0.284 0.045 0.208 0.046 0.209
Proportion of months with dual eligibility 2000–2002 0.213 0.402 0.066 0.234 0.089 0.276 0.050 0.208 0.121 0.317
Proportion of months with dual eligibility 2003–2005 0.232 0.415 0.093 0.279 0.113 0.304 0.072 0.246 0.141 0.336
Average distance to closest endoscopy provider, 2000–2002 1.256 3.363 0.951 1.938 1.416 2.622 3.612 5.385 2.695 4.508
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Variable CA CT GA IA KY
Sample size 86,843 23,402 10,316 22,799 18,203
Mean SD Mean SD Mean SD Mean SD Mean SD
Average distance to closest endoscopy provider, 2003–2005 1.257 3.318 0.954 1.942 1.487 2.692 3.554 5.354 2.676 4.489
Had CRC diagnosis by 2002 0.138 0.345 0.192 0.394 0.155 0.362 0.203 0.402 0.120 0.325
Had CRC diagnosis by 2005 0.158 0.365 0.207 0.405 0.169 0.375 0.214 0.410 0.135 0.342
Had breast cancer diagnosis by 2002 0.227 0.419 0.293 0.455 0.273 0.446 0.272 0.445 0.150 0.357
Had breast cancer diagnosis by 2005 0.241 0.428 0.306 0.461 0.288 0.453 0.285 0.451 0.162 0.369
Had irritable bowel disease in 2000–2002 0.015 0.123 0.014 0.116 0.013 0.112 0.009 0.094 0.012 0.111
Had irritable bowel disease in 2003–2005 0.016 0.125 0.017 0.130 0.015 0.120 0.010 0.098 0.012 0.109
Had HMO coverage 1998–1999 0.151 0.358 0.234 0.423 0.113 0.317 0.009 0.095 0.039 0.194
Had HMO coverage 2001–2002 0.109 0.312 0.124 0.330 0.056 0.231 0.004 0.065 0.022 0.147
Months with MA HMO coverage, 2000–2002 2.787 7.748 3.794 8.079 1.860 6.035 0.094 1.307 0.616 3.531
Months with MA HMO coverage, 2003–2005 0.577 3.474 0.157 1.805 0.652 2.966 0.333 2.370 0.097 1.449
Months with no Part B coverage, 2000–2002 0.109 1.158 0.065 0.836 0.087 0.967 0.037 0.560 0.055 0.819
Months with no Part B coverage, 2003–2005 0.103 1.499 0.036 0.915 0.039 0.910 0.009 0.452 0.026 0.769
Variable LA MI NJ NM UT WA
Sample size 15,717 25,692 35,378 7,439 8,777 17,511
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Female 0.678 0.467 0.713 0.453 0.673 0.469 0.655 0.475 0.674 0.469 0.696 0.460
Disability or ESRD original reason for enrollment in Medicare 0.002 0.046 0.004 0.066 0.001 0.037 0.003 0.056 0.003 0.057 0.004 0.064
Age 73–80 in 2000 0.346 0.480 0.387 0.490 0.384 0.490 0.342 0.470 0.360 0.480 0.384 0.490
Age 80? in 2000 0.126 0.330 0.151 0.360 0.145 0.350 0.128 0.330 0.141 0.350 0.158 0.360
White 0.787 0.410 0.824 0.381 0.887 0.317 0.850 0.357 0.971 0.168 0.931 0.253
Asian 0.002 0.043 0.005 0.070 0.008 0.090 0.002 0.043 0.006 0.077 0.023 0.151
African American 0.203 0.402 0.163 0.369 0.079 0.270 0.012 0.108 0.003 0.052 0.018 0.134
Hispanic 0.003 0.057 0.003 0.051 0.017 0.130 0.090 0.286 0.009 0.094 0.003 0.052
Native American 0.001 0.035 0.000 0.020 0.000 0.018 0.038 0.191 0.003 0.056 0.006 0.077
All other races/ethnicities 0.004 0.063 0.006 0.075 0.008 0.090 0.009 0.092 0.008 0.090 0.018 0.133
Moved 2000–2002 0.039 0.195 0.070 0.255 0.060 0.238 0.078 0.269 0.046 0.210 0.086 0.280
Moved 2003–2005 0.054 0.226 0.071 0.257 0.060 0.238 0.059 0.236 0.068 0.252 0.093 0.291
Proportion of months with dual eligibility 2000–2002 0.155 0.352 0.062 0.234 0.073 0.252 0.121 0.317 0.032 0.170 0.062 0.233
Proportion of months with dual eligibility 2003–2005 0.185 0.379 0.070 0.247 0.090 0.278 0.143 0.340 0.043 0.193 0.078 0.258
Average distance to closest endoscopy provider, 2000–2002 3.158 5.704 0.653 1.861 0.791 1.668 4.715 9.935 1.926 5.330 1.554 3.404
Average distance to closest endoscopy provider, 2003–2005 3.127 5.674 0.680 1.941 0.792 1.687 4.733 9.809 1.916 5.302 1.554 3.362
Had CRC diagnosis by 2002 0.112 0.316 0.176 0.381 0.133 0.340 0.141 0.348 0.135 0.342 0.159 0.366
Had CRC diagnosis by 2005 0.126 0.332 0.197 0.397 0.151 0.358 0.153 0.360 0.147 0.354 0.172 0.377
Had breast cancer diagnosis by 2002 0.147 0.354 0.291 0.454 0.160 0.366 0.248 0.432 0.266 0.442 0.316 0.465
Had breast cancer diagnosis by 2005 0.162 0.368 0.306 0.461 0.174 0.379 0.260 0.439 0.279 0.449 0.329 0.470
Had irritable bowel disease in 2000–2002 0.009 0.096 0.016 0.126 0.018 0.134 0.013 0.112 0.012 0.108 0.013 0.113
Had irritable bowel disease in 2003–2005 0.010 0.098 0.018 0.135 0.020 0.138 0.014 0.117 0.014 0.118 0.013 0.113
Had HMO coverage 1998–1999 0.157 0.364 0.070 0.255 0.131 0.337 0.093 0.291 0.126 0.332 0.154 0.361
Had HMO coverage 2001–2002 0.086 0.280 0.076 0.266 0.071 0.258 0.023 0.150 0.007 0.084 0.057 0.232
Months with MA HMO coverage, 2000–2002 1.973 6.121 1.747 6.130 1.861 6.162 1.143 4.112 0.130 1.579 2.044 5.942
Months with MA HMO coverage, 2003–2005 0.410 2.815 0.078 1.100 0.229 2.132 0.833 4.349 0.347 1.908 0.261 2.386
Months with no Part B coverage, 2000–2002 0.066 0.843 0.068 0.886 0.086 0.981 0.076 0.889 0.090 1.024 0.066 0.841
Months with no Part B coverage, 2003–2005 0.027 0.758 0.024 0.715 0.044 1.014 0.044 1.029 0.040 1.013 0.044 0.976
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State CA CT GA IA KY
Number PCSAs 336 71 116 224 144
Mean SD Mean SD Mean SD Mean SD Mean SD
Isolation index for African Americans 0.050 0.078 0.068 0.104 0.286 0.192 0.011 0.036 0.059 0.094
Isolation index for Hispanics 0.311 0.237 0.077 0.108 0.043 0.051 0.024 0.038 0.015 0.014
Isolation index for Asians 0.067 0.085 0.023 0.015 0.012 0.016 0.007 0.009 0.006 0.010
Isolation index for native Americans 0.022 0.057 0.004 0.006 0.004 0.003 0.004 0.011 0.004 0.005
Proportion of workforce who commute[60 min 0.102 0.059 0.086 0.060 0.094 0.042 0.049 0.026 0.094 0.048
Proportion of elderly with little/no English
language
0.286 0.168 0.152 0.098 0.200 0.199 0.081 0.130 0.104 0.155
Prop. area’s beneﬁciaries in Medicare HMO 2001 0.308 0.201 0.082 0.079 0.021 0.045 0.024 0.052 0.034 0.058
Prop. area’s beneﬁciaries in Medicare HMO 2004 0.277 0.185 0.059 0.067 0.048 0.030 0.056 0.063 0.043 0.048
State LA MI NJ NM UT WA
Number PCSAs 109 148 141 61 50 110
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Isolation index for African Americans 0.357 0.172 0.086 0.172 0.125 0.158 0.014 0.018 0.006 0.014 0.019 0.037
Isolation index for Hispanics 0.020 0.017 0.034 0.044 0.121 0.144 0.501 0.219 0.096 0.094 0.088 0.125
Isolation index for Asians 0.011 0.031 0.011 0.017 0.053 0.055 0.006 0.008 0.010 0.011 0.031 0.043
Isolation index for native Americans 0.012 0.028 0.013 0.026 0.002 0.002 0.139 0.271 0.026 0.060 0.055 0.130
Prop. workforce who commute[60 min 0.101 0.041 0.072 0.040 0.130 0.053 0.098 0.073 0.074 0.047 0.097 0.073
Proportion of elderly with little/no English 0.085 0.106 0.112 0.088 0.242 0.137 0.256 0.210 0.172 0.199 0.192 0.164
Prop. area’s beneﬁciaries in Medicare HMO 2001 0.081 0.131 0.021 0.036 0.116 0.048 0.056 0.110 0.037 0.057 0.151 0.137
Prop. area’s beneﬁciaries in Medicare HMO 2004 0.082 0.127 0.026 0.028 0.094 0.036 0.083 0.112 0.085 0.052 0.138 0.110
Table 6 Sample statistics for intermediate/community factors (counties): mean followed by standard deviation
State CA CT GA IA KY
Number of counties 58 8 118 99 120
Mean SD Mean SD Mean SD Mean SD Mean SD
Percent population in poverty 2000 13.419 4.890 6.513 1.758 15.015 5.386 8.792 2.032 16.698 6.411
Percent population in poverty 2003 12.853 3.820 7.063 1.723 15.382 4.671 9.026 1.789 16.892 5.379
Gini coefﬁcient of income disparity, 2000 0.448 0.023 0.429 0.041 0.443 0.044 0.404 0.022 0.457 0.040
Endoscopic providers per thousand, 2000–
2002
1.059 0.527 1.483 0.594 0.544 0.830 1.560 1.294 1.014 0.951
Endoscopic providers per thousand, 2003–
2005
1.841 3.946 0.928 0.728 4.117 10.983 2.208 3.272 2.826 15.999
Oncologists per thousand, 2000 0.074 0.067 0.092 0.081 0.044 0.102 0.035 0.147 0.029 0.083
Oncologists per thousand, 2003 0.170 0.142 0.304 0.201 0.115 0.202 0.064 0.284 0.067 0.176
Gastroenterologists per thousand, 2000 0.078 0.070 0.098 0.087 0.051 0.103 0.027 0.116 0.028 0.088
Gastroenterologists per thousand, 2003 0.178 0.157 0.333 0.200 0.137 0.229 0.072 0.347 0.068 0.158
State LA MI NJ NM UT WA
Number of counties 64 78 21 33 29 39
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Percent population in poverty 2000 19.281 5.475 10.355 2.894 7.500 3.460 19.670 5.308 11.272 4.177 12.663 3.332
Percent population in poverty 2003 19.169 4.329 10.769 2.424 8.550 3.540 18.918 4.957 10.717 3.560 12.664 2.651
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